Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Elena-Diana Chiru"'
Autor:
Tamas Fulop, Abdullah M Khan, Valentín Ortiz-Maldonado, Marcus Vetter, Rainer Wirth, Fabian Ullrich, Paul J Bröckelmann, Amin T Turki, Elena-Diana Chiru, Bastian von Tresckow, Raul Cordoba, Nina Rosa Neuendorff
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 12 (2024)
The treatment landscape for lymphoma and multiple myeloma, which disproportionally affect older adults, has been transformed by the advent of T cell-mediated immunotherapies, including immune checkpoint inhibition, T cell-engaging bispecific antibodi
Externí odkaz:
https://doaj.org/article/8afaf79800064ff3a516fd0cd7446516
Autor:
Dimitri Dettwiler, Elena-Diana Chiru, Eveline Daetwyler, Vérène Dougoud-Chauvin, Markus W. Gross, Christian Kurzeder, Alfred Zippelius, Andreas Schötzau, Marcus Vetter
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
BackgroundIn Switzerland, approximately 6000 new breast cancer cases and 1300 deaths are reported annually. Brain metastasis from breast cancer (BMBC) has a major effect on prognosis. This study aimed to identify prognostic factors for overall surviv
Externí odkaz:
https://doaj.org/article/dba5da9ff3b7439594f2e71c7e821db8
Autor:
Elena-Diana Chiru, Marcus Vetter
Publikováno v:
healthbook TIMES. Oncology Hematology, Vol 16, Iss 2 (2023)
Oncotype DX Breast Recurrence Score is a prognostic and predictive assay of 21 genes, initially designed for therapy planning in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-negati
Externí odkaz:
https://doaj.org/article/030dea86d45841de84103e367bbd2f4d
Autor:
Elena Diana Chiru, Anton Oseledchyk, Andreas Schoetzau, Christian Kurzeder, Raphael Mosimann, Marcus Vetter, Cvetka Grašič Kuhar
Publikováno v:
Diagnostics, Vol 14, Iss 1, p 97 (2023)
In patients with hormone receptor positive, human epidermal receptor 2 negative (HR+/HER2−) negative breast cancer (BC), the TAILORx study showed the benefit of adding chemotherapy (CHT) to endocrine therapy (ET) in a subgroup of patients under 50
Externí odkaz:
https://doaj.org/article/47fddb00d3164bbc9d1dfbc8044ad8bf